Home > Healthcare > Medical Devices > Diagnostic Devices > Critical Care Diagnostics Market

Critical Care Diagnostics Market Trends

Report ID: GMI9740
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Critical Care Diagnostics Market Trends

The rising the prevalence of chronic diseases and lifestyle-related disorders is a significant driver for market. These diagnostics enable healthcare providers to identify disease progression, monitor treatment efficacy, and make timely adjustments to treatment plans, improving patient outcomes.

According to the World Health Organization (WHO), in 2023, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year.
Similarly, as per the same report, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following cancer diagnostics were 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease.
Lifestyle-related disorders such as obesity, hypertension, and type 2 diabetes significantly increase the risk of severe health events like heart attacks, strokes, and kidney failure. Critical care diagnostics are essential for assessing the severity of these events and guiding appropriate medical interventions.
Innovations in diagnostic technologies, such as point-of-care testing, molecular diagnostics, and imaging modalities, have enhanced the ability to diagnose and monitor chronic diseases effectively. These advancements drive the demand for critical care diagnostics as they provide more accurate and timely information.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Critical care diagnostics industry size was worth USD 1.3 billion in 2023 and will grow at 5.5% CAGR between 2024 and 2032 due to escalating prevalence of chronic diseases and infectious outbreaks coupled with the emphasis on early detection and intervention.

The glucose diagnostic kits segment in the market will record USD 507.2 million by 2032, driven by the rising prevalence of diabetes and the importance of monitoring glucose levels in critical care settings.

U.S. critical care diagnostics industry size will expand at 5.1% CAGR from 2024 to 2032, attributed to advanced healthcare infrastructure, extensive research and development activities, and a strong emphasis on technological innovation.

Key players operating in the critical care diagnostics industry are Danaher Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Hologic, Inc., Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Nihon Kohden Corporation, and Nova Biomedical, among others.